Study of FVIIa Variant BAY86-6150 (B0189) in Subjects With Moderate or Severe Hemophilia Types A or B With or Without Inhibitors

Inclusion Criteria: * History of moderate or severe congenital hemophilia A or B with or without inhibitors to Factor VIII (FVIII) or Factor IX (FIX) * Male subjects 18-65 years of age inclusive * Able to dismiss factor replacement therapy during the course of the study unless required for the treatment of an acute bleeding episode * Written informed consent * Willing and able to comply with the requirements of the protocol * Have adequate venous access * Willing to use an effective method of contraception until Day 30 of their study participation Exclusion Criteria: * Received factor replacement therapy or treatment with any other procoagulant therapeutics, or any antifibrinolytic agents, including blood products, at anytime within 5 days prior to administration of investigational medicinal product (IMP) * Planned administration of factor replacement therapy or treatment with any other procoagulant therapeutics or any antifibrinolytic agents, including blood products, at anytime during the study period * Acute bleeding episode or any ongoing bleeding episode at any time within 7 days prior to administration IMP * Clinically relevant coagulation disorder other than congenital hemophilia A or B * History of angina or receiving treatment for angina * History of coronary atherosclerotic disease, disseminated intravascular coagulopathy, or stage 2 hypertension defined as systolic blood pressure (SBP) \>/= 160 mmHg or diastolic blood pressure (DBP) \>/= 90 mmHg * History of transient ischemic attack, stroke, myocardial infarction, coronary artery disease, congestive heart failure, or thromboembolic event * Active infection on day of IMP administration or septicemia at any time within 30 days prior to administration of IMP